The impact of low-dose anticoagulation therapy on peripheral artery disease: insights from the VOYAGER trial

Cardiovasc Res. 2020 Oct 1;116(12):e156-e158. doi: 10.1093/cvr/cvaa225.
No abstract available

Keywords: Atherothrombosis; Low-dose anticoagulation; Peripheral artery disease (PAD); VOYAGER trial.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blood Coagulation / drug effects*
  • Clinical Trials as Topic
  • Factor Xa Inhibitors / administration & dosage*
  • Factor Xa Inhibitors / adverse effects
  • Fibrinolytic Agents / administration & dosage*
  • Fibrinolytic Agents / adverse effects
  • Hemorrhage / chemically induced
  • Humans
  • Peripheral Arterial Disease / blood
  • Peripheral Arterial Disease / diagnosis
  • Peripheral Arterial Disease / drug therapy*
  • Peripheral Arterial Disease / mortality
  • Risk Assessment
  • Risk Factors
  • Rivaroxaban / administration & dosage*
  • Rivaroxaban / adverse effects
  • Treatment Outcome

Substances

  • Factor Xa Inhibitors
  • Fibrinolytic Agents
  • Rivaroxaban